47 results about "Immunostimulant" patented technology

The invention discloses an immunogenic composition containing a composite adjuvant as well as a preparation method and application of the immunogenic composition. The immunogenic composition comprises a gE-gI fusion protein, an immunopotentiator, namely, saponin QS-21, and a neutral liposome, the gE-gI fusion protein comprises a VZV gE, a connecting peptide and a VZV gI. The immunogenic composition provided by the invention only contains one immunopotentiator, can be applied to VZV vaccines, and solves the problems of relatively weak gE immunogenicity and relatively large clinical side reaction of the vaccines prepared in the prior art. The immunogenicity of the vaccine is equivalent to that of the Xinanlii, but the vaccine contains fewer immunopotentiators and has lower clinical side effects; in addition, the vaccine can also induce a gI specific antibody and gI specific CMI reaction, which is beneficial to further improvement of the effectiveness of the vaccine. In short, the immunogenic composition has good clinical application potential.

The invention discloses an immune agonist and a preparation method thereof, and relates to the technical field of immune agonist preparation, and the preparation method of the immune agonist comprises the following specific steps: S1, preparing a double-target immune agonist monomer; s2, preparing a cationic liposome inner core; s3, biomimetic cell membrane coating; and S4, finished product detection. According to the immune agonist and the preparation method thereof, in the preparation process, a continuous flow microreactor is used for two-step synthesis of a double-target monomer, a segmented precise temperature control mode is matched with microwave strengthening, the reaction period can be shortened, efficient entrapment of the agonist is achieved through a micro-reaction technology, and the problems that a traditional batch method is low in entrapment efficiency and uneven in particle size are solved; in addition, MDC cell membrane extraction is conducted through differential centrifugation, the integrity of the membrane is guaranteed, active targeting of a CD11c marker on the surface of the MDC cell membrane is achieved through a cell biomimetic membrane, and after lipidosome and membrane vesicles with the volume ratio being 3: 1 are fused, the in-vitro BMDC binding rate is increased compared with that of naked lipidosome.

The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the methods involve administering a composition comprising therapeutically effective amount of at least one immune stimulator to the subject. In some embodiments, a combination of at least two immune stimulators is used for the treatment. In some embodiments, the combination includes an alpha thymosin peptide and an additional immune stimulator, and / or optionally one or more additional anti-cancer agents.

Provided is an adjuvant composition comprising a glycoarchaeol and at least one immunostimulant selected from a Toll-like receptor (TLR) agonist and a saponin. The glycoarchaeol and / or immunostimulant may be present as a pharmaceutically acceptable salt. The adjuvant composition may be comprised together with an antigen in an immunogenic composition, such as a vaccine composition, which may be for use to induce an immune response in a subject. Further provided is use of the immunogenic composition to induce an immune response in a subject, particularly an immune response that comprises both a cell-mediated response and a humoral response.

The present disclosure provides compositions and methods for the delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse. The compositions comprise (i) a structure comprising an injectable polymer or scaffold comprising pores; (ii) lymphocytes disposed within the structure, (iii) at least one lymphocyte-adhesion moiety associated with the structure; and (iv) at least one lymphocyte-activating moiety associated with the structure, and optionally an immune stimulant.

A hetero-structured RNA with two 3′-overhangs and use thereof as an immune stimulant are provided.

The invention provides a personalized cancer vaccine based on apoptosis vesicles and a preparation method and application thereof, and belongs to the technical field of biological medicine, the personalized cancer vaccine comprises apoptosis vesicles, an immunologic stimulant and a biocompatibility carrier; the apoptosis vesicles are extracellular vesicles generated after tumor cells are subjected to apoptosis induction; the biocompatible carrier is a modified chitosan hydrogel, and the biocompatible carrier is a modified chitosan hydrogel; the immunologic stimulant is loaded in the apoptosis vesicle, and the apoptosis vesicle loaded with the immunologic stimulant is embedded into the modified chitosan hydrogel. According to the invention, apoptosis vesicles generated by induction of tumor cells of a patient are taken as a core, the apoptosis vesicles have a natural tumor antigen library and a strong immune activation capability, and personalized precise treatment can be realized; meanwhile, the invention provides a preparation method and application in postoperative tumor recurrence prevention and treatment, and provides technical support for clinical transformation.

The invention discloses a composite milk adjuvant, a preparation method and application of the composite milk adjuvant in vaccines, and belongs to the technical field of medicines. The technical problems to be solved are relatively weak cell immunocompetence, relatively poor immunogenicity and relatively weak immunoregulation capability. According to the technical scheme, squalene, polyoxyethylated castor oil 35 and poloxamer 407 are used as raw materials to prepare a basic formula of the milk adjuvant, an immunologic stimulant is added on the basis to prepare the composite milk adjuvant, and the physicochemical properties and safety of the composite milk adjuvant are represented. The synergistic effect of the milk adjuvant on humoral immunity and cellular immunity is further evaluated by being matched with a recombinant tuberculosis antigen Ag85B to immunize mice, and data support is provided for application of the milk adjuvant in development of novel vaccines such as tuberculosis vaccines and the like. The composite milk adjuvant prepared by the invention not only keeps good humoral immunity and induces generation of high-level IgG1 and IgG2a, but also remarkably improves the response level of cellular immunity.

A hetero-structured RNA with two 3′-overhangs and use thereof as an immune stimulant are provided.

The present disclosure relates to a method for predicting the response of a metastasis to immunotherapy in a metastatic colorectal cancer patient. The present disclosure also encompasses an immunotherapy for use in the treatment of a metastatic colorectal cancer in a patient in need thereof previously identified as having a metastasis responsive to immunotherapy and an immune-stimulating agent for use in the treatment of a metastatic colorectal cancer in a patient in need thereof previously identified as having a metastasis non-responsive to immunotherapy. The present disclosure also relates to a pharmaceutical composition comprising an immune-stimulating agent and retinoic acid for use in the treatment of a metastatic colorectal cancer in a patient in need thereof.

The present application provides an immunostimulant containing Lactobacillus helveticus, wherein the Lactobacillus helveticus has three functions: activation of dendritic cell-like cells, induction of immunoglobulin A (IgA) production, and induction of interleukin-12 (IL-12) production.

The invention provides a lipidoid Toll-like receptor agonist derivative as well as preparation and application thereof, and particularly provides a compound as shown in a formula I, a preparation method of the compound and application of the compound as a TLR7 and / or TLR8 agonist. The compounds can be used as immunostimulators and adjuvants.

The present invention relates to a composition for enhancing immunity, comprising, as an active ingredient, an enzyme-treated product of polysaccharides derived from a mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora, or a novel purified fraction thereof. According to the present invention, the composition for enhancing immunity, comprising, as an active ingredient, an enzyme-treated product of polysaccharides from a mixed extract of Angelica gigas, Cnidium officinale, and Paeonia lactiflora, or a novel purified fraction thereof, comprises specific types and contents of sugars. Thus, when macrophages, splenocytes, and NK cells are treated with the composition, the composition significantly increases the activities thereof, and therefore can be applied as an immunostimulant or a food composition for enhancing immunity.

Compositions containing a nucleic acid nanostructure having a desired geometric shape and immunostimulatory agent(s) bound to its surface are provided. The nanostructures can be, for example, in the form of a 6-helix bundle, or icosahedron, or a pentagonal bipyramid. The nanostructure design allows for control of the relative position and / or stoichiometry of the immunostimulatory agent(s) bound to its surface. The immunostimulatory agent(s) displayed on the nanostructure surface are arranged with the preferred number, spacing, and 3D organization to elicit a robust immune response. The displayed antigen can be a TLR agonist, such as a TLR9 agonist. The immunostimulatory compositions may thus be useful as immunogens, vaccines, adjuvants, and the like. Methods of inducing immune responses, and for targeted induction of TLR activation are also provided.

The present application provides novel compounds or pharmaceutically acceptable salts thereof having TLR4 activating effects, and useful as immunostimulants or adjuvants in vaccine or allergen immunotherapy. The present application provides a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof. In the formula (I), X, Y, Z and n are each as defined in the specification.[Formula 1]

To provide a composition for immunostimulation.SOLUTION: A composition for immunostimulation comprising, as an active ingredient, a bacterium phagocytosed by plasmacytoid dentritic cells (pDCs) to a predetermined degree or more and / or a bacterium binding to BDCA2.SELECTED DRAWING: None

This provides a novel material with immunostimulatory properties. [Solution] An immunostimulant comprising the cells of Pichia yeast or Torraspora yeast as an active ingredient; an immunostimulant food composition, an immunostimulant pharmaceutical composition, or an immunostimulant cosmetic composition comprising the immunostimulant; Pichia yeast with receipt number NITE AP-04248; Pichia yeast with receipt number NITE AP-04249; Torraspora yeast with receipt number NITE AP-04250; Torraspora yeast with receipt number NITE AP-04251.

This invention relates to the field of vaccine adjuvant technology, and discloses an oil-in-water adjuvant containing squalene and α-tocopherol, its preparation method, and its application. The preparation method includes the following steps: mixing squalene, α-tocopherol, and poloxamer to obtain an oil phase mixture; subjecting the oil phase mixture to high-speed shearing with an aqueous phase to obtain a pre-emulsion; and subjecting the pre-emulsion to high-pressure homogenization to obtain the oil-in-water adjuvant. This invention, through the synergistic effect of α-tocopherol and poloxamer, combined with a specific preparation process, solves the problems of poor stability and uneven particle size distribution in existing adjuvants. The adjuvant prepared by this invention exhibits excellent long-term physicochemical stability, with a Z-average particle size in the range of 100-300 nm and a polydispersity index (PDI) of less than 0.25, demonstrating good immunostimulant carrying capacity and immune enhancement effect.

The application provides a manganese dioxide nanomaterial, which comprises manganese dioxide nanoparticles and a carrier substance combined on the surface of the manganese dioxide nanoparticles; the carrier substance comprises CpG oligonucleotide and / or antigen; the antigen comprises protein antigen and / or polypeptide antigen. The manganese dioxide nanomaterial provided by the application greatly improves the immune stimulation of the immune adjuvant CpG, is used for improving the immune protection function of a vaccine, and solves the inherent defects that the oligonucleotide CpG as an immune stimulant is difficult to enter the lymph nodes of the body, and a large amount of CpG is needed to effectively improve the immune response; and as a vaccine adjuvant, the manganese dioxide nanomaterial can carry antigen, especially protein antigen, effectively improves the uptake of immune cells in the lymph nodes to the antigen, and thus improves the immunogenicity of the antigen. Meanwhile, the nanomaterial is biodegradable, and in a weak acid environment such as a lysosome, the nanomaterial can be gradually degraded into manganese ions (Mn 2+ ), and finally discharged out of the body.

The present invention is directed to a method for treating cancer by delivering lipid-nanoparticles (LNPs) encapsulating immunostimulant mRNA and bispecific antibody mRNA to cancer cells or intratumorally. The method comprises the step of administering mRNA-encapsulated LNPs to a tumor lesion of a subject having cancer. The immunostimulant mRNA-LNP activates immune cells around tumor, which work together with mRNA-LNP encoding bispecific antibody and PBMC to effectively target local and distant metastatic tumors. Preferred immunostimulants are GM-CSF and IL-12, and its combination.

To provide a novel immunostimulatory composition.SOLUTION: An immunostimulatory composition contains microalgae-derived extracellular membrane vesicles as an active ingredient.SELECTED DRAWING: Figure 1

Compounds can specifically activate TLR7. The compounds are useful because they can stimulate innate immunity. The compounds can be used in the treatment of conditions including cancer, viral infections and skin lesions. The compounds can optionally be formulated for enhanced penetration following topical administration, the composition preferably initiating a local specific inflammatory cytokine response while limiting undesirable erythema and other inflammatory reactions. Pharmaceutical compositions contain the compound and preferably an additional compound such as imiquimod and / or resiquimod (R848). A composition contains the compound and a compound can be used as a medicament. Other aspects, embodiments, advantages and applications will become clear from the further description herein.

The invention relates to the technical field of biomedical engineering, in particular to Pickering emulsion and a preparation method and application thereof. According to the Pickering emulsion provided by the invention, APS is selected as an immunologic stimulant and is combined with PLGA, so that the immunocompetence of PLGA as an adjuvant is enhanced; the PLGA-coated astragalus polysaccharide can prevent the antigen from being directly exposed in an organic solvent to influence the activity of the antigen; compared with PLGA nanoparticles, the Pickering emulsion has a larger specific surface area and can adsorb more antigens; the Pickering emulsion has good fluidity and can increase the interaction between the PLGA nanoparticles and cell membranes, when the PLGA nanoparticles are in contact with the APCs, a large number of antigens are absorbed by the APCs, and the activated APCs can carry a large number of nanoparticles to enter lymph nodes, so that the Pickering emulsion has good lymph node targeting property. Upon uptake of a large number of antigens, the immune cells induce strong cellular or humoral immune responses in various ways.

The inventors found that the overexpression of innate immune response and T cell exhaustion pathways is much more pronounced in pigs than in cattle, making pigs less likely than cattle to mount adaptive immune responses and humoral immune responses. This paper presents an innovative strategy to improve the abnormal immune responses in pigs by simultaneously inducing effective cellular and humoral immune responses and applying T cell agonists as new vaccine adjuvants. This result can provide important clues for understanding the differences in immune responses between cattle and pigs, while presenting a method for maximizing immune responses and vaccine efficacy, which are less expressed in pigs than in cattle.

The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. The receptor modulators can be formulated to form pharmaceutical compositions comprising the disclosed compounds or pharmaceutically acceptable salts or prodrugs thereof. The compositions may be used for managing CXCR4 related conditions, typically prevention or treatment of viral infections abnormal cellular proliferation, retinal degeneration, inflammatory diseases, or as an immunostimulant or immunosuppressant or for managing cancer and may be administered with another active ingredient such as an antiviral agent or chemotherapeutic agent.

To provide a gout ameliorating agent and a gout ameliorating composition having excellent gout ameliorating action and high safety, and to provide a liver function improving agent and a liver function improving composition having excellent immunopotentiating action. To provide an immunopotentiator and a composition for immunopotentiation having high safety, an anti-aging agent and a composition for anti-aging having excellent anti-aging action and high safety, an anti-inflammatory agent and a composition for anti-inflammation having excellent anti-inflammatory action and high safety, a hair grower and a composition for hair growth having excellent hair growing action and high safety, and an antioxidant and a composition for antioxidant having excellent antioxidant action and high safety.SOLUTION: The gout improver, the liver function improver, the immunopotentiator, the anti-aging agent, the anti-inflammatory agent, the hair grower or the antioxidant contains an extract of Peucedanum japonicum Thunb.SELECTED DRAWING: None

The application relates to the technical field of medicines, and particularly discloses a novel immune stimulant, a preparation method and application thereof. The immune stimulant comprises an alpha-mannose modified imidazoquinoline derivative, an N-acetyl cysteine modified cytosine-guanine dinucleotide, a glycyrrhetinic acid-polyethylene glycol derivative, a phytic acid-glycine oligomer, a medicinal excipient and water for injection, three modified active ingredients are bridged by the phytic acid-glycine oligomer as a bridging unit, and a ternary coordination complex is formed through dynamic non-covalent coordination. The preparation method comprises the following steps: after raw materials are pretreated, the active ingredients are premixed, dissolved and solvent is recovered, then dynamic coordination reaction, ultrafiltration purification and concentration are carried out, and finally, a finished product is obtained through double-cavity preparation forming. The immune stimulant can be used for preparing a tumor immunotherapy, an anti-infection treatment, an immune deficiency disease auxiliary treatment drug or a vaccine adjuvant, and has the advantages of high active ingredient stability, good in-vivo delivery efficiency and outstanding synergistic effect.

Purified antigens are usually weakly immunogenic and require the addition of immunostimulatory agents and / or delivery systems to generate robust antigen-specific responses. The present application relates to self-assembling polypeptides that may be conjugated to immunogens and have the ability to self-assemble into immunogen-displaying nanofilaments that activate the humoral and cellular immune responses. The self-assembling polypeptide comprises an amino acid sequence having at least 60% identity with the sequence of the R4 and R5 domains from a Curli-specific gene A (CsgA) protein. The present application also relates to nucleic acids encoding the self-assembling polypeptide / immunogen conjugates, to compositions and vaccines comprising the self-assembling polypeptide / immunogen conjugates or nucleic acids, as well as to methods for inducing an immune response against an immunogen and / or for preventing and / or treating a microbial infection, cancer or any pathological conditions in which vaccination may be useful such as autoimmune diseases and allergies, in a subject.

To provide novel lactic acid bacteria and an immunostimulant using said lactic acid bacteria. [Solution] The present invention provides an immunostimulant comprising Lactobacillus helveticus, wherein Lactobacillus helveticus has three functions: activation of dendritic cell-like cells, induction of IgA production, and induction of IL-12 production.